Apolipoprotein E genotype in patients with Alzheimer's disease: Implications for the risk of dementia among relatives
- Farrer, L.A. (Lindsay)
- Cupples, L.A. (Adrienne)
- Duijn, C.M. (Cornelia) van
- Kurz, A.
- Zimmer, R.
- Müller, U. (Ulrich)
- Green, R.C. (Robert)
- Clarke, V.
- Shoffner, J.
- Wallace, D.C.
- Chui, H. (Helena)
- Flanagan, S.D. (Steven)
- Duara, R. (Ranjan)
- St. George-Hyslop, P. (Peter)
- Auerbach, S.A.
- Volicer, L.
- Wells, J.M. (John)
- Broeckhoven, C. (Christine) van
- Growdon, J.H. (John)
- Haines, J.L. (Jonathan)
DOIAbstract
Numerous studies have shown that the risk of Alzheimer's disease (AD) is associated with the dose of the ϵ4 allele of apolipoprotein E (ApoE). However, more than one third of AD patients lack ϵ4 and many persons having ϵ4 survive cognitively intact to old age. We evaluated the lifetime risk of disease in 3,999 first‐degree relatives of 549 probands who met the criteria for probable or definite AD and whose ApoE genotypes were known. ApoE genotypes for relatives were not determined. After age 65 the risk among relatives was proportional, as much as 7 to 10% a
Add to ORKG